Skip to main content

Table 2 Body and liver weight in Swiss albino mice

From: Pharmaceutical efficacy of harmalol in inhibiting hepatocellular carcinoma

Group no.

Treatment

No. of Mice

Final weight (g)

1st week

7th week

14th week

21st week

I

Control (untreated)

5

Body

25.3 ± 2.1

25.7 ± 2.3

26.1 ± 2.2

26.3 ± 2.1

Liver

1.69 ± 0.13

1.68 ± 0.12

1.69 ± 0.14

1.69 ± 0.13

II

Harmalol treated

5

Body

25.6 ± 2.3

26.2 ± 2.1

26.8 ± 2.4

25.1 ± 2.3

Liver

1.66 ± 0.11

1.57 ± 0.12

1.58 ± 0.14

1.55 ± 0.13

III

CCl4 treated

5

Body

25.2 ± 3.1

22.6 ± 3.1

19.1 ± 3.4

17.3 ± 3.2*

Liver

1.62 ± 0.28

1.56 ± 0.22

1.43 ± 0.32

1.35 ± 0.36*

IV

DEN treated

5

Body

24.5 ± 1.9

20.2 ± 1.5

17.5 ± 1.1

15.6 ± 1.2*

Liver

1.50 ± 0.27

1.41 ± 0.25

1.33 ± 0.14*

1.19 ± 0.11*

V

DEN+CCl4 treated

5

Body

20.2 ± 2.9

18.3 ± 3.6

15.4 ± 2.7

13.6 ± 1.6*

Liver

1.45 ± 0.16

1.32 ± 0.19

1.23 ± 0.33*

0.96 ± 0.9*

VI

Pre-treatment with harmalol

5

Body

25.5 ± 2.5

25.3 ± 2.8

24.6 ± 2.8

24.1 ± 2.3*

Liver

1.59 ± 0.17

1.57 ± 0.22

1.56 ± 0.27

1.49 ± 0.23*

VII

Post-treatment with harmalol

5

Body

20.6 ± 2.4

18.2 ± 2.6*

22.8 ± 2.2*

24.9 ± 1.8

Liver

1.47 ± 0.24

1.33 ± 0.29*

1.46 ± 0.25*

1.66 ± 0.23

  1. Mice were sampled 21 weeks after the initiation of treatment, and values represented means ± SE
  2. *Significantly different from the control groups (p < 0.05)